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Cholesterol esters are a key ingredient of foamy cells in
atherosclerotic lesions; their formation is catalyzed by two
enzymes: acyl-CoA:cholesterol acyltransferases (ACATs; also
called sterol O-acyltransferases, or SOATs) ACAT1 and ACAT2.
ACAT1 is present in all body cells and is the major isoenzyme in
macrophages. Whether blocking ACAT1 benefits atherosclero-
sis has been under debate for more than a decade. Previously,
our laboratory developed a myeloid-specific Acat1 knockout
(KO) mouse (Acat1M/M), devoid of ACAT1 only in macro-
phages, microglia, and neutrophils. In previous work using
the ApoE KO (ApoE/) mouse model for early lesions,
Acat1M/M significantly reduced lesion macrophage content
and suppressed atherosclerosis progression. In advanced
lesions, cholesterol crystals become a prominent feature. Here
we evaluated the effects of Acat1M/M in the ApoE KO mouse
model for more advanced lesions and found that mice lacking
myeloid Acat1 had significantly reduced lesion cholesterol crys-
tal contents. Acat1M/M also significantly reduced lesion size
and macrophage content without increasing apoptotic cell
death. Cell culture studies showed that inhibiting ACAT1 in
macrophages caused cells to produce less proinflammatory
responses upon cholesterol loading by acetyl low-density lipo-
protein. In advanced lesions, Acat1M/M reduced but did
not eliminate foamy cells. In advanced plaques isolated from
ApoE/ mice, immunostainings showed that both ACAT1 and
ACAT2 are present. In cell culture, both enzymes are present in
macrophages and smooth muscle cells and contribute to choles-
terol ester biosynthesis. Overall, our results support the notion
that targeting ACAT1 or targeting both ACAT1 and ACAT2 in
macrophages is a novel strategy to treat advanced lesions.
Atherosclerotic cardiovascular disease remains a major con-
tributor to human morbidity and mortality worldwide. As
reviewed in Refs. 1–3, during the early stages of atherogenesis,
chronic inflammation causes monocytes to adhere to activated
endothelial cells, infiltrate into the subendothelial space of the
arterial wall, and transform into macrophages. Under sustained
hyperlipidemic condition, macrophages that are retained in the
intimal layer of the artery continue to take up cholesterol and
other lipids, mostly in the form of denatured lipoproteins. Upon
entering the cell interior, lipoprotein-derived cholesterols are
converted to cholesterol esters (CEs)3 for storage, causing the
cholesterol-loaded cells to become foamy. In advanced athero-
sclerotic lesions, in addition to cholesterol, several oxysterols,
either synthesized enzymatically or produced through auto-ox-
idation, etc., also accumulate, as reviewed in Ref. 4. The unest-
erified forms of oxysterols at high concentrations can cause
various toxic effects to cells (5). As the lesion continues to
develop, foamy macrophages secrete various inflammatory
cytokines, which stimulate the smooth muscle cells to migrate
from the medial layer to the intimal layer of the artery and to
proliferate. In advanced lesions, both macrophages and smooth
muscle cells become foamy cells; they secrete matrix metallo-
proteinases, which degrade collagen and other extracellular
matrix proteins, cause plaque instability, and eventually lead to
plaque rupture.
In macrophages and other cell types, CEs accumulated in the
cytosolic compartment appear as lipid droplets and cause the
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cells to look foamy in appearance. These lipid droplets exist in a
dynamic state: re-esterification by the enzyme acyl-CoA:cho-
lesterol acyltransferase (ACAT; also called sterol O-acyltrans-
ferase (SOAT)) and hydrolysis by neutral cholesterol ester
hydrolases constitute the cholesterol/CE cycle, causing CEs to
undergo continuous turnover, as reviewed in Ref. 6. For esteri-
fication, there are two ACAT genes, SOAT1 and SOAT2, encod-
ing two distinct enzymes: ACAT1 (7) and ACAT2 (8 –10). Both
enzymes use long-chain fatty acyl-CoAs, and sterols with 3--
OH, including cholesterol and various oxysterols as their sub-
strates (11, 12). ACAT1 and ACAT2 are integral membrane
proteins located in the ER region, and they are allosterically
activated by cholesterol or oxysterols. In humans, ACAT1 is
ubiquitously expressed in essentially all body cells; high levels of
ACAT2 are mainly found in intestinal enterocytes (13, 14). Low
levels of ACAT2 are also detectable in many other cell types,
and their expression levels can become much elevated under
various disease states (15). For example, in human and in mouse
macrophages, ACAT1 is the major isoenzyme (16); however, in
human and mouse advanced atherosclerotic lesions, a signifi-
cant amount of ACAT2 becomes clearly detectable (17). In nor-
mal adult human hepatocytes, the ACAT2 protein expression is
low (13); however, its expression becomes highly elevated in a
certain subset of human hepatocarcinoma (12), as well as in
patients with gallstones (18). In mouse, under normal condi-
tions and in a mouse model for diet induced insulin resistance,
ACAT2 is the major isoenzyme in hepatocytes (19). Both
ACAT1 and ACAT2 are present in mouse adipocytes and play
important roles in adipogenesis (20). For CE hydrolysis, there
are a number of candidate hydrolytic enzymes, all capable of
hydrolyzing CEs. The two major hydrolytic enzymes identified
in macrophages are neutral cholesteryl ester hydrolase 1 (21,
22) and lipoprotein lipase, as reviewed in Ref. 23. Lipoprotein
lipase also catalyzes the hydrolysis of retinyl esters and diacyl-
glycerol (24).
Whether ACAT should be considered as a target for athero-
sclerosis treatment has been under debate for many years, as
reviewed in Ref. 15. Regarding the pharmacological approach,
two different ACAT inhibitors (CI 1011 and pactimibe) tested
safe in humans, reached clinical trial phase 3 stage but were
both abandoned at the end, in part because neither one was
found to augment the actions of statin, which is the clinically
approved drug for treating atherosclerosis. Because the small
molecule inhibitor approach always stands the chance of pro-
ducing off-target side effect(s), it is important that the pros and
cons of ACAT blockage be carefully evaluated by using a differ-
ent approach, the gene knockout approach in animals. This is
an area where much disagreement occurred among different
groups of investigators. Early studies by Yagyu yet al. (25)
showed that in mouse models for atherosclerosis progression,
whole body Acat1 knockout (KO) (Acat1/) attenuated ath-
erosclerosis lesions and diminished lesion macrophage con-
tent. Accad et al. (26) acquired similar results but concluded
that Acat1/) actually enlarged atherosclerotic lesions. In the
same mouse models, Acat1/ also caused dry eye syndrome,
as well as severe cutaneous xanthomatosis, which is a rare skin
disease not associated with diet-induced atherosclerosis in
humans. Acat1/ also drastically shortened the life spans of
the hyperlipidemic mice (26). Whole-body Acat1/ also
affected the proliferation rates of stem cells within the bone
marrow and caused a significant increase in leukocyte counts in
the blood (27, 28). To minimize the side effects of whole body
Acat1/, a milder approach was undertaken (29), by perform-
ing transplant experiments using bone marrow cells from
either WT mice or from Acat1/ mice as the donor cells and
the irradiated hyperlipidemic mice as the recipient mice. The
results showed that when compared with bone marrow cells
from the WT mice, those from Acat1/ mice altered lesion
composition and significantly increased lesion development. In
contrast, very recently, Yamazaki et al. (22) performed similar
experiments and received outcomes that are at variance with
those reported by Fazio et al. (29). It is known that bone marrow
contains myeloid cells and lymphoid cells; both myeloid cells
and lymphoid cells affect atherosclerosis at various stages. The
variable effects observed by different groups using bone mar-
row isolated from the Acat1/ mice in transplant experiments
might be caused by the lack of ACAT1 in macrophages as well
as by the lack of ACAT1 in lymphoid cells (i.e. T cells and B
cells). To focus on studying the roles of ACAT1 in macro-
phages, Huang et al. (28) developed a myeloid-specific Acat1
KO mouse (Acat1M/M); these mice lack Acat1 only in the
myeloid cell lineage, which includes macrophages, microglia,
and neutrophils. The myeloid-specific Acat1 KO mice do not
exhibit dry eye syndrome nor leukocytosis (28). When crossed
with the ApoE KO (ApoE/) mouse model for atherosclerosis,
myeloid Acat1 KO significantly reduced lesion macrophage
content and suppressed atherosclerosis progression; mechanis-
tic studies showed that ACAT1 deficiency in macrophages
slows down the entry of these macrophages into the subendo-
thelial layer of the arterial vessel (28).
During various stages of atherosclerosis, in addition to CEs,
cholesterol crystals, often referred to as cholesterol clefts, also
develop and accumulate within lesions. These crystals cause
damage to lysosomal membranes, trigger the formation of
inflammasomes, and cause severe adverse immune responses
(30, 31). Studies in macrophage cell culture showed that cho-
lesterol crystal formations are initiated within the late endo/
lysosomes (32, 33). Cell culture studies showed that without
cholesterol acceptors present in the cell exterior, ACAT block-
age in macrophages caused a significant increase in the choles-
terol crystal content that led to detrimental consequences;
however, when external cholesterol acceptors were present,
ACAT blockage did not induce cholesterol crystal formation,
and no detrimental consequence could be observed (34). At the
in vivo level, whether ACAT blockage affects cholesterol crystal
formation in atherosclerotic lesions had not been closely exam-
ined, because of one important technical limitation: in mouse
models, cholesterol crystals become a prominent feature within
the necrotic core in advanced atherosclerotic lesions, and it
takes continuous feedings of a atherosclerosis diet for 15–20
weeks to develop advanced lesions in mouse. Both the
total Acat1 KO mouse and the myeloid-specific Acat1 KO
(Acat1M/M) mouse exhibit normal life spans. However, in
the ApoE KO genetic background, presumably because of exag-
gerated xanthomatosis, the whole-body Acat1 KO mouse had a
much-shortened life span and began to die 8 –10 weeks after
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continuous high-cholesterol diet feeding. The much-shortened
life span of the Acat1//ApoE/ mouse prohibited the inves-
tigators from pursuing the effect of whole body Acat1 KO in
advanced atherosclerotic lesions. Recently, Huang et al. (28)
showed that when fed continuously with a high-cholesterol
diet, the Acat1M/M/ApoE/ mouse fared much better in
terms of survival rate. Here we took advantage of this opportu-
nity and investigated the effects of myeloid-specific Acat1 KO
in the ApoE KO mouse model for advanced and reported our
findings.
Results
Silencing myeloid Acat1 reduces the development of
advanced atherosclerosis in ApoE/ mouse
To assess the effect of a prolonged modified Paigen diet treat-
ment on the overall health of the ApoE/ and ApoE//
Acat1M/M mice, we monitored the mouse weights and sur-
vival rates over a 20-week period. As shown in Fig. 1A, mice
from all groups (ApoE/, ApoE//Acat1M/M, and ApoE//
Acat1/) consistently gained weight after week 4. By week 20
the ApoE//Acat1M/M mouse exhibited 16.6% higher
weight gains than the ApoE/ control mice. We suspect that
this is because the ApoE/ mouse exhibits subcutaneous xan-
thomas, which has been demonstrated by multiple groups. As
detailed in our previous work, this skin disease is exacerbated in
the ApoE//Acat1M/M mouse and may contribute to the
weight gain throughout the duration of the diet. Interestingly,
we found that myeloid-specific Acat1 knockout was protected
from the occurrence of early death associated with the total
Acat1 knockout mouse. On average, 76% of ApoE//
Acat1M/M mice survived the extended diet study, unlike the
ApoE//Acat1/ mice, which only survived to week 9. Thus,
the ApoE//Acat1M/M mouse provides a unique opportu-
nity to study the effects of knocking out macrophage Acat1 in
late stage atherosclerosis. To compare the atherosclerotic bur-
den in 20-week modified Paigen diet–fed ApoE/ and ApoE//
Acat1M/M mice, we isolated whole aortic tissues from
these mice and performed Enface analysis by staining them
with Sudan IV, a red -naphthol diazo dye that stains neutral
lipids and other lipid materials. The quantification of total
Sudan IV staining revealed that the ApoE//Acat1M/M
male mice exhibited 42.7% less area percentage of atheroscle-
rotic plaques than those of the ApoE/ control, indicating
that knocking out myeloid Acat1 slowed the progression of
advanced lesions (Fig. 2B). We next performed H&E staining of
aortic sections taken from both mouse types and found that the
atheroma lesion areas, measured in the ascending and descend-
ing aortas, were significantly reduced by 36.7 and 49.3%,
respectfully, in the ApoE//Acat1M/M mice (Fig. 2, D and
E). These results extend our 12-week study reported previously,
which demonstrated that ApoE//Acat1M/M mice are pro-
tected from early to mid-stage atherosclerosis (28).
Figure 1. Silencing myeloid Acat1 rather than silencing Acat1 globally extends the life span of modified Paigen diet–fed ApoE/ mice. A, body weights
of male ApoE/, ApoE//Acat1M/M, and ApoE//Acat1/ mice fed a modified Paigen diet for 20 weeks. B, survival curves of ApoE/, ApoE//Acat1M/M,
and ApoE//Acat1/ mice.
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Previously, we showed that the mechanism by which myeloid
Acat1 deletion prevents early lesions likely involves the reduc-
tion of macrophage content within the ascending atheroscle-
rotic plaques (28). Here, by performing fluorescent confocal
microscopic analysis using CD68 to monitor macrophage pres-
ence, we again observed a marked reduction of macrophage
content, in the intimal layer of both the ascending plaques and
the descending plaques from ApoE//Acat1M/M mice, rel-
ative to those from the ApoE/ control mice (Fig. 3). In addi-
tion to macrophages, the atherosclerotic lesions contain other
immune cell types, especially the T lymphocytes. During ather-
osclerosis development and progression stages, T cells exist in
several subtypes that play both pro-inflammatory and anti-in-
flammatory roles (35, 36). CD45 is a pan-leukocyte marker that
recognizes all T cells and other white blood cells but does not
recognize myeloid cells or smooth muscle cells. Here we used
CD45 to examine the leukocyte contents within the advanced
lesions by performing confocal microscopy. The results (Fig. 4)
showed that in advanced lesions, silencing myeloid Acat1 in the
ApoE/ mice tends to reduce plaque leukocyte contents, sug-
gesting that Acat1M/M may indirectly impact leukocyte
abundance in atherosclerotic lesion. The significance of this
finding is not clear at present and requires further investigation.
Inhibiting ACAT1 in macrophages attenuated the
proinflammatory responses to acetyl LDL-mediated
cholesterol loading
Macrophages exhibit plastic phenotypes. Their abilities to
participate in various immune responses is controlled by the
environment. In atherosclerosis, chronic inflammation that
occurs at the surface areas of the aortic vessel attract monocytes
and macrophages to migrate and adhere to the activated endo-
thelium and become resident cells within the intimal region
of the aortic tissue. Under hypercholesterolemia, cholesterol
loading causes macrophages to become more inflammatory, in
part by up-regulating the expressions of several proinflamma-
tory response genes (reviewed in Ref. 37). In our current study,
the results described in Fig. 3 showed that in the ApoE/
mouse model for advanced lesion, myeloid Acat1 deletion
caused a significant decrease in macrophage content in the
lesion. To provide a plausible cellular basis for this finding, we
hypothesize that ACAT1 blockage may cause macrophages to
Figure 2. Deleting myeloid Acat1 reduces the atherosclerotic burden in ApoE/ mice fed a modified Paigen diet for an extended period of time. A,
enface staining of whole aortas isolated from ApoE/ and ApoE//Acat1M/M mice treated with modified Paigen diet for 20 weeks. B and D, quantitation of
lesion area detected in male (B) and female (C) aortas. D and E, H&E staining of cross-sections of ascending (D) and descending (E) aortas from male ApoE/ and
ApoE//Acat1M/M mice. The data are reported as means  S.E. *, p  0.05; **, p  0.01.
Figure 3. Deleting myeloid Acat1 in the ApoE/ mice reduces macro-
phage presence in advanced aortic lesions. A, confocal microscopy analy-
sis of macrophage content (CD68 stain in green) in aortic sections of ascend-
ing lesions. B, CD68-positive area found in the aortic sections of descending
lesions of ApoE/ and ApoE//Acat1M/M mice. Areas outlined in white
represent atherosclerotic plaques. The data are reported as means  S.E. *,
p  0.05.
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produce less proinflammatory responses upon cholesterol
loading. To test this possibility, we isolated peritoneal macro-
phages from ApoE/ mice and preincubated the cells without
or with a potent and specific small molecule ACAT1 inhibitor
K604 at 0.5 M (38) for 18 h. For cholesterol loading, we treated
the cells with high concentration (100 g/ml) of acetylated low-
density lipoprotein (AcLDL), a denatured form of LDL that
produces cholesterol loading in macrophages (39, 40), for 1 day.
Afterward, we harvested the cells to monitor their inflamma-
tory responses by performing Western blotting analysis (Fig.
5A) and mRNA analysis (Fig. 5D). For Western blotting analy-
sis, we chose to monitor two proteins: iNOS and COX2. These
are two of the nonsecretory proteins in macrophages that are
known to respond positively to pro-inflammatory signals,
including lipopolysaccharides (41). The results showed that in
peritoneal ApoE/ macrophages, loading AcLDL significantly
induced iNOS expression; under this condition, inhibiting
ACAT1 with K604 significantly attenuated the induced expres-
sion of iNOS (Fig. 5C). Additional results showed that loading
AcLDL also significantly induced COX2 expression; inhibiting
ACAT1 with K604 tended to attenuate the induced expression
of COX2, but the effect of K604 did not reach statistical signif-
icance (Fig. 5B). For mRNA analyses, we monitored nine pro-
inflammatory response genes, including the genes that encode
iNos and Cox2. The results showed (Fig. 5D) that loading
AcLDL significantly induced the expressions of all nine genes;
inhibiting ACAT1 with K604 significantly attenuated the
induced gene expressions of iNos, Ccl5, Cox2, and Tnf, but did
not significantly attenuate the induced gene expressions of
Mcp1, Ccl3, Ccl7, and Cxcl10. The peritoneal macrophages
employed in Fig. 5 were isolated from mice lacking ApoE. To
test the generality of findings described in Fig. 5, we repeated
the experiment by using the mouse RAW 264.7 cell line. This
cell line has been employed as a model cell for macrophages by
many investigators. The results showed that loading AcLDL in
RAW macrophages significantly up-regulated the expressions
of both COX2 and iNOS proteins, and inhibiting ACAT1 with
K604 significantly attenuated the induced expressions of both
proteins (Fig. 6, A and C). Additional results (Fig. 6E) showed
that loading AcLDL in RAW macrophages significantly
induced the expressions of seven of the nine genes tested; inhib-
iting ACAT1 with K604 significantly attenuated the induced
gene expressions of iNos, Cox2, and Tnf but did not attenuate
the induced gene expressions of Mcp1, Ccl3, Ccl5, and Ccl7.
The result presented in Fig. 6 largely corroborated with the
result presented in Fig. 5 and supports the hypothesis that
under hypercholesterolemia, ACAT1 blockage in macrophages
causes these cells to exhibit a less inflammatory phenotype;
the less inflammatory phenotype causes their sparse presence
within the plaque.
We next monitored cholesterol crystal contents in the
lesions after the H&E staining of aortic cross-sections isolated
from the ApoE/ and ApoE//Acat1M/M mice. As dem-
onstrated in Fig. 7, when compared with the control ApoE/
mice, the ApoE//Acat1M/M mice possess significantly
fewer cholesterol crystals in the necrotic core (depicted by
space devoid of H&E stain). Quantitation using National Insti-
tutes of Health ImageJ software revealed that reductions in cho-
lesterol crystals in the ascending and descending aortas were
by 88 and by 41%, respectfully. Results of a TUNEL analysis
revealed that there was no difference in the number of apopto-
tic cells present within the plaques of ApoE/ and ApoE//
Acat1M/M mice (Fig. 8).
Both ACAT1 and ACAT2 are expressed in advanced
atherosclerotic lesions
Given that ACAT1 is a major contributor to foam cell forma-
tion in macrophages (16), we next wanted to compare the per-
centage of foam cells within the advanced lesions of 20-week
fed ApoE/ and ApoE//Acat1M/M mice. We stained aor-
tic sections with Oil Red O to detect neutral lipids in foam cells
(Fig. 9). We found that surprisingly, although there were signif-
icant reductions in the overall plaque burden as demonstrated
in Fig. 2, the level of neutral lipid containing areas within the
ascending aorta of the ApoE//Acat1M/M mouse was actu-
ally comparable with that of the ApoE/ mouse. We specu-
lated that in advanced lesions, in addition to ACAT1 in macro-
phages, ACAT2 and/or nonmacrophage ACAT1 may play
active roles in CE formation within the atherosclerosis plaques.
To address this question, we used immunofluorescence
microscopy to visualize ACAT1 and ACAT2 protein expres-
sion within the ascending lesions of ApoE/ and ApoE//
Acat1M/M mice (Fig. 10). Our results showed that ACAT2
was present in aortic lesions of both mouse lines. These findings
support and extend the early results by Sakashita et al. (17). Our
results also show that ACAT1-positive cells were observed
within the medial layers of plaques from both mouse groups.
Together, these results suggest that in the advanced lesions, in
addition to ACAT1 in macrophages, ACAT2 in macrophages
and smooth muscle cells as well as nonmacrophage ACAT1
play active roles in neutral lipid content build up, by contribut-
ing to cholesteryl ester formation through their cholesterol
acyl-transferase activity.
Figure 4. Deleting myeloid Acat1 in the ApoE/ mice tends to reduce
leukocyte contents in advanced lesions. A and C, confocal microscopy
analysis of leukocyte contents based on the pan-leukocyte marker CD45 in
aortic sections of ascending lesions from ApoE/ (A) and ApoE//
Acat1M/M mice (C). The original magnification of confocal microscopy in A
and C is 10. B and D, zoomed-in views of CD45 (green) and 4,6-diamino-2-
phenylindole (DAPI, blue) signals. E, percentage area positive for CD45 was
calculated per plaque area. The data are reported as means  S.E.
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Figure 5. Inhibiting ACAT1 ameliorates AcLDL-induced iNOS expression in peritoneal macrophages isolated from ApoE/ mice. Peritoneal macro-
phages isolated from ApoE/ mice were treated without or with the small molecule ACAT1 inhibitor K604 at 0.5 M for 18 h and then treated without or with
100 g/ml of AcLDL for 24 h. A, Western blotting analysis of COX2 and iNOS protein expressions. B and C, densitometry analysis of COX2 (B) and iNOS (C) protein
expressions. D, QPCR analysis of various pro-inflammatory response genes. The data are reported as means  S.E. *, p  0.05.
Figure 6. Blocking ACAT1 ameliorates AcLDL induced iNOS and COX2 expressions in RAW macrophages. RAW macrophages were treated without or
with K604 at 0.5 M for 18 h and then treated without or with 100 g/ml of AcLDL for 24 h. A and C, Western blotting analysis of COX2 and iNOS protein
expression. B and D, densitometry analysis of COX2 (B) and iNOS (D) protein expression. E, mRNA levels of pro-inflammatory response genes. The data are
reported as means  S.E. *, p  0.05; **, p  0.01.
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25-Hydroxycholesterol induces ACAT1 and ACAT2 protein
expression in vascular smooth muscle cells and induces ACAT2
protein expression in macrophages
In advanced lesions, oxysterols are known to build up at high
concentrations. To examine whether ACAT2 can play an active
role in CE formation when vascular smooth muscle cells and
macrophages are activated by oxysterols, we took an in vitro
approach to monitor its expression in response to 25-hydroxy-
cholesterol (25HC). We chose 25HC because its ample pres-
ence in the atherosclerotic plaques had been demonstrated (4).
In addition, Wang et al. (19) demonstrated that in cells of
hepatic and intestinal origin, saturated fatty acids or sterols/
oxysterols including 25HC added to culture media protects the
ACAT2 protein, but not the ACAT1 protein, against protea-
some mediated degradation.
We treated RAW macrophages and primary mouse vascular
smooth muscle cells (VSMCs) with various concentrations of
25HC (0.5, 1, 5 M) for 48 h and then monitored ACAT1 and
ACAT2 expression by performing Western blotting and QPCR
analyses. The results of Western blotting analysis showed that
25HC increased the expression of both ACAT1 and ACAT2
proteins in VSMCs, yet in macrophages only ACAT2 proteins
responded to 25HC (Figs. 11 and 12). QPCR analyses showed
that in VSMCs, mRNA levels of ACAT2 were not impacted by
25HC, whereas higher concentrations (5 M) did induce Acat1
mRNA levels. In macrophages, mRNA levels of nether the
Acat1 nor the Acat2 were impacted by 25HC. Together, these
results show that in VSMCs, 25HC induces both ACAT1 and
ACAT2 protein. Regarding the mechanism of actions of 25HC
on ACATs, for ACAT1, the mechanism may involve transcrip-
tion activation, perhaps in a smooth muscle cell–specific man-
ner, because in macrophages, 25HC does not increase ACAT1
protein expression in macrophages. For ACAT2, the mecha-
Figure 7. Silencing myeloid Acat1 in ApoE/ mice reduces cholesterol
cleft development in advanced atheromas. H&E staining of cross-sections
isolated from the ascending (A) and descending (B) aortas of 20-week fed
ApoE/ and ApoE//Acat1M/M mice. The area devoid of H&E stain was
quantified as positive cholesterol cleft area (examples depicted by the
arrows). The data are reported as means  S.E. *, p  0.05.
Figure 8. TUNEL analysis of apoptosis in aortic lesions. Cell death was
detected by TUNEL analysis in ApoE/ (top panel) and ApoE//Acat1M/M
mice (middle panel) fed a modified Paigen diet for 20 weeks. Aortic lesions
were stained with markers for TUNEL (red) CD68 (green) and SMA (blue).
DNase-treated aortic sections (bottom panel) were used as a positive control
for TUNEL staining. The number of TUNEL-positive cells were quantified per
lesion area. The data are reported as means  S.E. *, p  0.05.
Figure 9. Neutral lipid content is diminished in the descending aortic
plaques but remains unchanged in plaques located in the aortic arch of
ApoE//Acat1M/M mice. Oil Red O staining of cross-sections of advanced
lesions found in the ascending (A) and descending (B) aortas of ApoE/ and
ApoE//Acat1M/M mice. The data are reported as means  S.E. *, p  0.05.
Figure 10. Advanced atherosclerotic lesions from ApoE/ and ApoE//
Acat1M/M mice express ACAT2 protein. A, ACAT1 expression (depicted in
fuchsia) detected by confocal microscopy analysis of ascending aorta cross-
sections from ApoE/ and ApoE//Acat1M/M mice. B, immunofluores-
cence staining of ACAT2 (fuchsia), CD68 (green), and SMA (blue) in late stage
lesions from ApoE/ and ApoE//Acat1M/M mice. The data are reported
as means  S.E. *, p  0.05.
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nism may involve stabilizing against its degradation, in both
smooth muscle cells and macrophages, similar to the one
recently demonstrated in hepatocytes and intestinal entero-
cytes (19).
To test the effect of 25HC on overall CE formation in RAW
macrophages and in VSMCs, we measured CE formation by
using a radioactive assay in intact cells, in which we added
radiolabeled oleate (complexed to BSA) to cells in culture for a
given amount of time, and then measured the level of radiola-
beled CEs formed after performing TLC analysis of the lipid
extractions. The results showed that at 5 M 25HC significantly
induced CE formation in both RAW macrophages and VSMCs
(Fig. 13); upon treatment with K604, an ACAT1-specific small
molecule inhibitor (38), the CE formation was reduced by 80%,
providing evidence that in cells treated with 25HC, ACAT1
remains as the major CE-forming enzyme in both macrophages
and VSMCs. To determine the contribution of ACAT2 to the
overall CE formation in 25HC-treated RAW macrophages and
Figure 11. 25-Hydroxycholesterol stimulates both ACAT1 and ACAT2 protein expression in vascular smooth muscle cells. A and D, Western blotting
analysis of primary VSMC ACAT2 (A) and ACAT1 (D) expression in response to (0.5, 1, and 5 M) 25HC treatment (48 h). B and E, quantitation of protein expression
of ACAT2 (B) and ACAT1 (E). C and F, expression levels of ACAT2 (C) and ACAT1 (F) mRNA in 25HC-treated VSMCs detected by QPCR. The data are reported as
means  S.E. *, p  0.05.
Figure 12. A and D, 25HC-treated RAW 264.7 macrophages exhibit elevated ACAT2 protein expression Western blotting analysis of ACAT2 (A) and ACAT1 (D)
expression in RAW macrophages treated with 25HC (0.5, 1, and 5 M) for 48 h. B and E, quantitation of protein expression of ACAT2 (B) and ACAT1 (E). C and E,
QPCR analysis of ACAT2 (C) and ACAT1 (F) mRNA levels in 25HC-treated RAW macrophages cells. The data are reported as means  S.E. *, p  0.05.
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in VSMCs, we added pyripyroprene A (PPPA), an ACAT2-spe-
cific small molecule inhibitor at 1 and 5 M to determine
whether certain percentage of total ACAT activity can be inhib-
ited by PPPA in these cells (43). The results indicate that
although not statistically significant, there is a trend toward a
reduction in CE formation, in response to PPPA in both RAW
macrophages and in VSMCs (by 35 and 27% reduction, respect-
fully). These results indicate that upon stimulation by 25HC,
ACAT1 is a major isoform in macrophages and VSMCs, and
ACAT2 may play a secondary role, contributing to 30% of
overall CE formation activity. These results provide a plausible
explanation for our observation made in vivo (described in Fig.
9); namely, in the absence of ACAT1 in macrophages, plenty of
foam cells are present in advanced lesions from the ApoE//
Acat1M/M mice. CEs present in these foam cells can be
attributed to the nonmacrophage ACAT1 (VSMC-specific), as
well as ACAT2 present in both macrophage and VSMCs within
the plaques.
Discussion
Whether blocking ACAT1 in macrophages is pro-athero-
sclerotic or anti-atherosclerotic has been under debate for
many years. The results presented in the current work show
that in a mouse model for advanced atherosclerotic lesions, lack
of myeloid ACAT1 caused less macrophage presence, signifi-
cantly reduced lesion size and the cholesterol crystals, without a
detectable increase in apoptotic index within the lesion.
These results confirm and extend our previous results
reporting the effects of myeloid ACAT1 deficiency in the
same mouse model for early atherosclerotic lesions (28) and
show that in advanced lesions, myeloid selective silencing of
ACAT1 is atheroprotective.
The results of the cell culture study presented here showed
that inhibiting ACAT1 causes macrophages to produce less
inflammatory responses upon cholesterol loading by denatured
LDL (AcLDL). These results provide a plausible explanation for
the sparse presence of lesion macrophages in the ApoE//
Acat1M/M mice: in atherosclerosis, ACAT1 blockage in
macrophages causes these cells to be less responsive to choles-
terol loading and exhibit a less inflammatory phenotype; this
less inflammatory characteristic slows down their presence
within the plaque. At present, it is not clear why ACAT1 block-
age causes macrophages to become less inflammatory. Interest-
ingly, in a previous study, we had found that (41) inhibiting
ACAT1 causes macrophages grown in culture to produce less
inflammatory responses upon treatment with lipopolysaccharide,
the key bacterial endotoxin that drives acute inflammation in var-
ious immune cells. Lipopolysaccharide enters the cell interior and
acts mainly via the Toll-like receptor (TLRs) signaling. It is possible
that in macrophages, cholesterol loading activates the TLRs to
mediate the proinflammatory responses (44–46); ACAT1 block-
age may directly or indirectly attenuate the signaling activities of
the TLRs to suppress the proinflammatory responses. This and
other possibilities require further investigation.
In our current study, we also show that, in the advanced
lesions isolated from the ApoE//Acat1M/M mice, a signif-
icant amount of residual foamy cells, marked by the neutral
lipid staining dye Oil Red O, are still present (Fig. 6). These
findings correlate well with the results demonstrating the sig-
nificant presence of nonmacrophage ACAT1, in the medial
layer of the plaques as well as the presence of ACAT2 present in
both the intimal and the medial layer of the plaques (Fig. 7).
Earlier, Rong et al. (47) performed studies in cell culture and
demonstrated that ACAT1 in smooth muscle cells contributes
to foam cell formation. Our current study provides the in vivo
proof that indeed, there is ample ACAT1 present in foamy
smooth muscle cells. Regarding the presence of ACAT2 in ath-
erosclerotic lesions: Sakashita et al. (17) demonstrated that
in the advanced human and mouse atherosclerotic lesions,
ACAT2 is present; most of the ACAT2 signal was localized to
the macrophage-rich region. Here we confirmed and extended
the findings by Sakashita et al. by showing that in a mouse
model for advanced lesion, a significant amount of ACAT2 sig-
nals are present in regions of the lesion in which both macro-
phages and smooth muscle cells reside. To evaluate the relative
Figure 13. 25HC enhances cholesterol ester formation in RAW macrophages and VSMCs. Shown is cholesterol ester formation (measured by a radioactive
oleate pulse assay) in RAW macrophages (A) and VSMCs (B) in response to 25HC with or without ACAT1 inhibitor K604 or ACAT2 inhibitor PPPA. The data are
reported as means  S.E. *, p  0.05.
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contribution of ACAT1 versus ACAT2 in cholesterol esterifi-
cation in macrophages and in smooth muscle cells, we per-
formed experiments in cell culture, using the ACAT1-specific
inhibitor K604 and the ACAT2-specific inhibitor PPPA as
tools. The results show that in both macrophages and smooth
muscle cells, either under basal conditions or after cells were
treated with 25HC, ACAT1 remains as the major isoenzyme in
cholesterol esterification in these cells. The physical presence
of ACAT2 in these cells could be demonstrated by Western
blotting, and radioactive oleate pulse assays showed that the
contribution of ACAT2 is perhaps up to 20 –30% of the overall
cholesterol esterification process. Still, ACAT2 may play even
more significant roles in foam cell formation in vivo. This ques-
tion can only be addressed by further experimentation. Our
current work shows that, in advanced lesions, both ACAT1 and
ACAT2 are present in smooth muscle cells and contribute to
foam cell formation. In the future, it would be interesting to test
whether blocking ACATs in smooth muscle cells only would
benefit atherosclerosis development and progression.
The system employed in our current study has several limi-
tations. First, the myeloid cell lineage includes neutrophils,
dendritic cells, and eosinophils, in addition to monocytes/
macrophages. We cannot rule out the possibility that the ben-
eficial phenotype observed in the myeloid-specific Acat1 KO
was due to the lack of ACAT1 in monocytes/macrophages only.
The other limitation is that only one mouse model, the
ApoE/ KO mouse, for atherosclerosis was used. The validity
of this interpretation needs to be further validated by using
different animal models for advanced atherosclerosis.
Our work supports the work of other investigators, who took
the small molecule ACAT inhibitors approach and showed that
either by using an ACAT1-specific inhibitor K604 (38, 48) or by
using the isotype-nonspecific ACAT inhibitors including CI 1011
(49, 50), F1394 (47, 51), or pactimibe (52), all of which demon-
strated reductions in atherosclerotic lesions in preclinical models,
without overt systemic or plaque toxicity. Based on these previous
results and our current work, we recommend the use of ACAT
inhibitors to target advanced lesions. For efficacy, an inhibitor that
inhibits both ACAT1 and ACAT2 would be more efficient. For
safety reasons, an inhibitor that blocks ACAT1 with higher
potency than inhibiting ACAT2 would be more appropriate.
When macrophages were treated with isotype nonspecific
ACAT inhibitors under the condition in which cellular lipid efflux
was minimal, the inhibitors caused excess free cholesterol built up
inside the cells and produced detrimental consequences (33, 53).
Because the actions of the ACAT inhibitors depend on the lipid
efflux system to produce efficient cholesterol removal from the cell
interior, we recommend that in the future, patients to be selected
for ACAT inhibitor anti-atherosclerosis clinical trials should first
be screened to carry no monogenic mutations in genes involved in
the cellular lipid efflux process.
Experimental procedures
Mice
Homozygous ApoE/ knockout mice (C57BL/6) were pur-
chased from The Jackson Laboratory. The ApoE//Acat1/
and ApoE//Acat1M/M mice (generated by crossing the
LyzMCre, ApoE/, and Acat1Flox/Flox mice) were created as
previously described (28). For atherosclerosis studies, the mice
at postnatal day 21 were fed a standard chow diet for 8 weeks
and then treated with an atherogenic diet (designated here as
modified Paigen diet; 1.25% cholesterol, 35 kCal from fat) pur-
chased from Research Diet (catalog no. 99020201) for an addi-
tional 20 weeks. The body weights and rates of survival were
recorded once every week to monitor the overall health of the
animals. Mice that exhibited extreme weight loss, extensively
large xanthomas, skin ulcers, or loss of mobility were eutha-
nized, and the dates of death were noted. All mouse work was
approved by the Dartmouth College Institutional Animal Care
and Use Committee and followed the guidelines of the National
Institutes of Health.
Histological characterization of atherosclerotic plaques
Most of the procedures employed here were based on proce-
dures described by Huang et al. (28) with minor modifications.
To characterize atherosclerosis in ApoE/ and ApoE//
Acat1M/M mice, we euthanized the mice and isolated whole
aortas using a dissecting microscope. The aortic tissues were
fixed in 10% formalin and preserved in paraffin or OCT blocks
for sectioning. For Enface staining, we incubated whole aortas
with Sudan IV (a neutral lipid stain) for 10 min and then washed
them with 70% ethanol and PBS. The Sudan IV–positive area
was determined using ImageJ software, by first converting the
images to 8 bit, then setting the threshold for positive stain, and
finally measuring the percentage area using the analyze/mea-
sure function. For histological analysis of plaque lesion size, we
stained paraffin sections of ascending and descending plaques
with H&E staining. To quantify in ImageJ, the selection tool was
used to encircle the plaques within the aortic sections. The total
lesion area was calculated by summing the areas calculated for
each identified plaque. Cholesterol crystal area was determined
by measuring the areas devoid of H&E staining within the
necrotic cores of the lesions (51). Cross-sectional slices of aor-
tas were also stained with Oil Red O (ORO) to detect the neutral
lipid content within the plaques using techniques described in
our previous work (28). In short, sections were washed with
PBS, incubated with 0.3% ORO (made in isopropanol) for 15
min, and washed 20 times with H2O before being mounted
with glycerol and a coverslip. H&E- and ORO-stained sec-
tions were visualized with an Olympus IX73 inverted fluo-
rescence microscope.
Immunofluorescence microscopy
The immunofluorescence microscopic methods described in
Ref. 28 were used to quantify the macrophage contents, leuko-
cyte contents, apoptotic cells, ACAT1, and ACAT2 protein
expressions within the aortic plaques isolated from ApoE/
and ApoE//Acat1M/M mice (28). Frozen OCT sections
were thawed, blocked with 3% BSA, washed with TBST, and
then stained with one of the primary antibodies: anti-CD68,
anti–smooth muscle actin (SMA), anti-ACAT1 DM102, anti-
ACAT2 DM56 (13), rabbit polyclonal anti-ACAT2 antibody
(19), or rat anti-CD45 (Thermofisher) overnight at 4 °C. The
sections were then washed with TBST and incubated with
Alexa Fluor– conjugated secondaries. For TUNEL staining, we
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followed the protocol provided by the manufacturer (Roche).
The OCT aortic sections were washed with TBST, fixed in 4%
paraformaldehyde, permeabilized with 2% Triton X-100 and
1% sodium citrate, and then incubated with the TUNEL sub-
strate mixture (5 l of terminal deoxynucleotidyltransferase
enzyme  45 l of fluorescein label solution) for 1 h at 37 °C.
The sections were then stained with CD68 and SMA antibodies
overnight. The sections were also treated with 100 units DNase
for 15 min to serve as a positive control for TUNEL staining.
After incubating with secondary antibodies, the sections were
washed and mounted with anti-fade medium. We utilized Zeiss
LS510 and LSM 880 confocal microscopes to visualize the
images and take pictures. To quantify the fluorescence signal of
positively stained cells, we used ImageJ software. We changed
the image to 8-bit, set the threshold, drew a circle around the
lesion area with the selection tool, and then measured the pos-
itive signal within the encircled region. The fluorescence within
the regions was then summed to quantify the total area positive
for each stain.
Peritoneal macrophages and RAW 264.7 macrophages
To isolate peritoneal macrophages we injected 8-week-old
ApoE/ mice with thioglycollate using a sterile 27-gauge nee-
dle. The 4% thioglycollate (Sigma T9032) media were prepared
in H2O and autoclaved and then aged for several weeks in the
dark at room temperature. until it turned brown. Four days
later, the mice were sacrificed, cleaned with 70% ethanol, and
injected with 4 –5 ml of Hanks buffer into the intraperitoneal
space. The mice were put on an orbital shaker for 2 min to wash
the peritoneal space. A small opening near the abdomen was
cut to expose the peritoneal cavity; a 19-gauge needle was used
to retrieve the fluid in the cavity. The cells were spun down at
1200 rpm and then plated in a 6-well dish in media containing
DMEM  10% fetal calf serum  penicillin/streptomycin. Usu-
ally cells isolated from one mouse were used for a 6-well plate.
2.5 h after cells plating, the cells were washed with PBS to elim-
inate nonadherent cells and replenished with fresh growth
medium. Experimental treatments were performed 24 h post
seeding. The cells were treated without or with 0.5 M K604,
with 0.1% DMSO for 18 h, and then cells were fed without or
with AcLDL at a concentration of 100 g/ml for an additional
24 h. AcLDL was prepared as described in Ref. 54. RAW 264.7
macrophages were cultured in DMEM containing 10% heat-
inactivated bovine calf serum and penicillin/streptomycin. The
cells were plated in a 12-well dish at a density of 2.5  105
cells/well.
Primary vascular smooth muscle cells
To isolate primary vascular smooth muscle cells, we used a
procedure described by Kuang et al. (55). In short, the aortas
were collected from WT mice; forceps were used to remove the
adventitia and endothelial layer from the aortic tissue. The
remaining tissue was cut into small pieces and digested with
collagenase and elastase for 1 h. The cells were then collected
and plated in a dish with DMEM/Ham’s F-12 medium  10%
bovine calf serum for several days. VSMCs that migrated from
the tissue were trypsinized, replated, and allowed to propagate.
The primary VSMC culture was maintained in DMEM/Ham’s
F-12 medium  10% calf serum  penicillin/streptomycin and
split into a 6-well dish at 4  10 5 cells/well. To study how
RAW macrophages and WT VSMCs respond to 25HC, when
cells reached 80% confluent, we treated these cells with vari-
ous concentrations of 25HC (0, 0.5, 1.0, 5.0 M) for 48 h and
then harvested the cells for Western blotting or RT-PCR anal-
ysis. 25HC was solubilized in ethanol to prepare a working
stock of 12.4 mM.
Western blotting analysis
For Western blotting analysis of ACAT1 and ACAT2 protein
expression, the procedure described in Ref. 13 was used. RAW
macrophages and WT VSMCs cells were harvested in 10% SDS
and lysed with a 21-gauge syringe. The protein concentration of
the supernatant was determined by the Lowry protein assay.
The lysates were run on a 10% gel and transferred to a nitrocel-
lulose membrane for 4 h. After blocking in 5% milk in TBST
for 1 h, the membranes were incubated with a polyclonal anti-
ACAT1 antibody (DM102), an antibody against ACAT2
(DM56) (13), or the anti-ACAT2 antibody prepared by Dr. Bo-
Liang Li and Dr. Bao-Liang Song (19). -Tubulin (from Gen-
Script) was used as a loading control. To detect COX2 and
iNOS protein expression, antibodies against COX 2 used were
from Santa Cruz Biotechnology; antibodies against iNOS used
were from Abcam. Lysates were prepared in radioimmune pre-
cipitation assay buffer (plus protease inhibitor 1:100) and
briefly sonicated for 5 s on ice. After centrifugation the lysates
were run on a 10% gel and transferred to nitrocellulose mem-
brane in Towbin buffer. The intensities were normalized to
-tubulin expression.
RT-PCR analysis
To isolate RNA from cells, we added TRIzol reagent directly
to the cells and followed the manufacturer’s instructions
(Thermo Fisher Scientific). The RNA was dissolved in water
and then treated with DNaseI (Ambion). 1 g of RNA was used
to make cDNA using the BioBad iscript cDNA synthesis kit.
QPCR was performed with Bio-Rad Syber green mix using an
Applied Biosystems Step One RT-PCR system. The following
primers were used to detect the genes of interest: ACAT1 PF,
5-AGCCCAGAAAAATTTCATGGACACATACAG-3; ACAT1
PR, 5-CCCTTGTTCTGGAGGTGCTCTCAGATCTTT-3;
ACAT2 PF, 5-TTTGCTCTATGCCTGCTTCA-3; ACAT2
PR, 5-CCATGAAGAGAAAGGTCCACA-3; -actin PF, 5-
CAACGAGCGGTTCCGAT-3; and -actin PR, 5-GCCACA-
GGATTCCATACCCA-3. The Ct values were calculated
and normalized to the control group (cells treated with solvent
only). Primers used to monitor genes that respond to proin-
flammatory signals were as described in Ref. 41.
[3H]Oleate pulse to measure cholesterol ester biosynthesis in
intact cells
The procedures described in Ref. 42 were employed to mea-
sure ACAT activity in intact cells. RAW Macrophages and WT
VSMCs were plated into a 12-well dish and treated with or
without K604 (ACAT1-specific inhibitor (38) or PPPA, an
ACAT2-specific inhibitor (43). To initiate the pulse, the cells
were incubated with radiolabeled C18:1 conjugated to BSA at
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37 °C. 20 min after the substrate was added, we washed the cells
three times with PBS. The cells were then lysed in NaOH, and
10 l of the lysate was used for protein determination. Total
lipids were extracted using the Folch method. The lipids were
then dried down with N2, resuspended in ethyl acetate, and
loaded onto a TLC plate. The [3H]cholesterol ester band (iden-
tified by iodine staining) was scraped off the plate and read in a
scintillation counter.
Statistical analysis
For mouse studies five to eight mice per mouse line were used
to compare atherosclerosis progression. Unless stated, only
male mice were employed. For in vitro studies, all experiments
were performed two or three times, each with replicates. The
results were quantified using Microsoft Excel and Prism
GraphPad. The results are expressed as means  S.E. Two
tailed t tests were performed to evaluate the significance among
the experimental groups.
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